SecBot SecBot
8-K ·Filed Jun 2, 2026

FBRX

Forte Biosciences, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-253436
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine annual meeting filing with no earnings or operational news. The equity plan approval enables future equity grants but does not trigger immediate dilution. Monitor for subsequent option grants or S-8 filings that would indicate actual share issuance.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.00
T+0 close · Jun 2, 2026 · via day close
Latest settled
+352.88%
T+60 · $76.99
Vs SPY
+350.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $17.00entry
  2. T+1 · 6mo ago −1.82%α −2.23% · $16.69
  3. T+5 · 5mo ago −1.06%α +2.76% · $16.82
  4. T+20 · 5mo ago +23.06%α +24.06% · $20.92
  5. T+60 · 3mo ago +352.88%α +350.38% · $76.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended and restated 2021 Equity Incentive Plan (adding 1,850,000 new shares for a total reserve of 5,190,000 shares) and re-elected three Class III directors. The filing is a routine governance update with no material financial data or operational changes.

Key Facts

  • Stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 11,911,879 votes for, 3,997,050 against, and 351,042 abstentions.
  • The plan reserves 5,190,000 shares total, including 1,850,000 newly requested shares.
  • Three Class III directors (Steven Kornfeld, Scott Brun, Paul A. Wagner) were re-elected.
  • KPMG LLP was ratified as independent auditor for FY2026 with 17,722,893 votes for.
  • Advisory vote on executive compensation passed with 12,143,153 votes for.
  • No officer departures, no financial results, and no guidance were reported.

Financial Impact

No financial figures reported; the equity plan adds 1,850,000 new shares to the reserve, representing potential future dilution of approximately 9% of the 20,478,817 shares outstanding.

dilution

Risk Factors

  • Potential future dilution from equity awards under the approved plan.
  • No cross-filing context provided; no other corporate events to assess.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-253436
Document: d110060d8k.htm0001193125-26-253436
Document: 0001193125-26-253436-index-headers.html0001193125-26-253436
Document: 0001193125-26-253436-index.html0001193125-26-253436
Document: 0001193125-26-253436.txt0001193125-26-253436

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026